Astellas Pharma to Acquire Iveric Bio for US$5.9 B

By Ayush Saxena

Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)

Published: 10 May-2023

DOI: 10.3833/pdr.v2023.i5.2781     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a bid to bolster its ophthalmology portfolio, Astellas has agreed to acquire Iveric Biofor US$40 per share in cash, representing a total equity value of approximately US$5...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details